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Abstract
Solid tumours account for 90% of all cancers. Gene therapy represents a potential new modality
for their treatment. Up to now, several approaches have been developed, but the most efficient
ones are the viral vector based gene therapy systems. However, viral vectors suffer from several
deficiencies: firstly most vectors currently in use require intratumoural injection to elicit an effect.
This is far from ideal as many tumours are inaccessible and many may have already spread to other
parts of the body, making them difficult to locate and inject gene therapy vectors into. Second,
because of cell heterogeneity within a given cancer, the vectors do not efficiently enter and kill
every cancer cell. Third, hypoxia, a prevalent characteristic feature of most solid tumours, reduces
the ability of the viral vectors to function and decreases viral gene expression and production.
Consequently, a proportion of the tumour is left unaffected, from which tumour regrowth occurs.
Thus, cancer gene therapy has yet to realise its full potential.
The facultative or obligate anaerobic bacteria have been shown to selectively colonise and
regerminate in solid tumours when delivered systemically. Among them, the clostridial spores were
easy to produce, stable to store and safe to use as well as having extensive oncolytic ability.
However, research in animals and humans has shown that oncolysis was almost always interrupted
sharply at the outer rim of the viable tumour tissue where the blood supply was sufficient. These
clostridial spores, though, could serve as "Trojan horse" for cancer gene therapy. Indeed, various
spores harbouring genes for cancerstatic factors, prodrug enzymes, or proteins or cytokines had
endowed with additional tumour-killing capability. Furthermore, combination of these "Trojan
horses" with conventional chemotherapy or radiation therapies often significantly perform better,
resulting in the "cure" of solid tumours in a high percentage of animals.
It is, thus, not too difficult to predict the potential outcomes for the use of clostridial spores as
"Trojan horse" vectors for oncolytic therapy when compared with viral vector-mediated cancer
therapy for it be replication-deficient or competent. However, to move the "Trojan horse" to a
clinic, though, additional requirements need to be satisfied (i) target tumours only and not
anywhere else, and (ii) be able to completely kill primary tumours as well as metastases. Current
technologies are in place to achieve these goals.
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Background
Gene therapy represents a potential new modality for the
treatment of cancer and it is developing with a very fast
pace [1]. By the end of 2006, 854 protocols have been pro-
posed or trailed in the clinic setting for various cancers,
accounting for 66.6% of all gene therapy trials in humans
[2]. This has reflected the fact that cancer has become the
leading causes of death in Western world [3].
The key to a successful gene therapy is the vector system.
Various vectors have been developed with unique fea-
tures, including viral and non-viral based therapy systems.
Although each has its own advantages and disadvantages,
the replication-competent oncolytic viral vectors are the
most promising amongst existing ones [4,5]. However,
due to the complex nature of cancers, these vectors suffer
from several deficiencies: firstly the majority of vectors
currently in use requires intratumoural injection to elicit
an effect. While this might be useful in some cases, it has
limited applicability and, in fact, far from ideal as many
tumours are inaccessible and spread to other areas of the
body making them difficult to locate and treat. Second,
most vectors do not have the capacity to efficiently enter
and kill every tumour cell. Consequently, a proportion of
the tumour mass is left unaffected, from which tumour
regrowth occurs [6]. Although modest therapeutic
responses have been associated with the convincing trans-
gene expression in tumour tissues isolated from patients,
unequivocal proof of clinical efficacy is yet to be achieved.
It is, thus, fair to say that cancer gene therapy has yet to
realise its full potential.
Of all cancer diagnosed, 90% of these are solid tumours.
Recent understanding of the unique pathology of solid
tumours has shed light on the disappointing nature of
these new therapies and now demands rational and inno-
vative design of vectors. All solid tumours, when they
grow more than 2 mm diameter in size, undergo angio-
genesis that results in biological changes and adaptive
metabolisms, i.e.: formation of defective vessels, appear-
ance of hypoxic areas, and emergence of heterogeneous
tumour cell population [7]. This micro milieu provides a
haven for anaerobic bacteria. The strictly anaerobic
Clostridia have several advantages over others as clostridial
spores specifically colonise and germinate into vegetative
cells in the hypoxic regions of solid tumours, causing
tumour lysis and destruction. Early trials in the 70's of
non pathogenic strains in human had shown plausible
safety. However, existing knowledge indicated that oncol-
ysis was almost always interrupted sharply at the outer rim
of viable tumour tissue, thus, combinational approaches
have to be implemented, such as with radiofrequency
therapy [8,9]. A new trial of a non pathogenic strain of C.
novyi in combination with microtubule-interacting chem-
otherapeutic agents, including vinorelbine and docetaxel
and demonstrated very promising results. A phase 1 trial
of the combined approach in patients is in progress [10].
The intrinsic property of tumour-targeted colonisation of
clostridia enables them to serve as "Trojan horses" for the
delivery of genes for cancer therapy. Indeed, clostridial
spores that were genetically manipulated to harbour genes
for cancerstatic factors, prodrug converting enzymes, or
cytokines to improve their innate oncolytic activity have
been developed, including our work and others [11,12].
Furthermore, these vectors used in combination with con-
ventional chemotherapy or radiation therapies often per-
form better [12]. The notable advantages of using
clostridial spores are not only their innate ability for
tumour colonisation and destruction, but also the seem-
ingly unlimited capacity of these vectors to carry exoge-
nous genes. This characteristic beckons for the
development of novel ideas to equip clostridial spores
with gene combinations that may break immune suppres-
sion or elicit a strong anti-tumour response to eliminate
tumour metastases, the ultimate cause of cancer death
[13].
This review briefly describes the viral vectors, including
the replication defective vectors, the targeted vectors and
replication-competent oncolytic vectors, and their use in
cancer gene therapy as well as their advantages and disad-
vantages. Subsequently, we will focus on the development
of clostridial spores as "Trojan horse" vectors for cancer
therapy, the mechanisms involved, and the foreseeable
promises and problems when compared with existing
viral vector systems.
The development and use of viral vector systems 
for cancer gene therapy
(A) Retroviral vector systems
Murine Moloney leukaemia virus (MoMLV)-based retro-
viral vector is one of the earliest systems that were devel-
oped for gene therapy. The vector has unique ability to
transduce dividing cells [14]. Tumour cells are growing
fast and continuously dividing, such as in the case of gli-
oma, providing a rational for in vivo use of the vector sys-
tem. However, studies in animal models have shown that
poor vector penetration is always a problem in vivo.
MoMLV vector rarely travelled away from the injection
sites [15]. Due to this relative inefficiency of transducing
target cells, replication competent MoMLV has been
developed. A recent report from Kasahara's group showed
complete transduction of human U87 glioma xenografts
in nude mice after a single intracranial (i.c.) injection of
replication-competent MoMLV [16]. Viral envelope was
stained positively in glioma cells away from the injection
sites. Most importantly, no virus was detected in any non-
tumour tissues, showing strict tumour specificity. In
another study, replication competent retrovirus harbour-Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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ing a herpes simplex thymidine kinase (HSV TK) gene was
able to sensitize glioma cells in Lewis rats and achieved an
up to 20% longer-term survives (40 days).
Overall, more than 23% of all gene therapy trials in
patients for various diseases have used a replication-defec-
tive or competent MoMLV vector system. Existing studies
in animal experiments have shown that the vector system
was relatively safe and non-toxic. The case against retrovi-
ral vector systems is potential problems related to activa-
tion of cellular oncogenes and inactivation of tumour
suppressor genes by insertional mutagenesis. This was
true in the case of using MoMLV to transducer bone mar-
row stem cells for the therapy of severe combined
immune deficiency syndrome (SCIDs), 4 out of 11 treated
children have now developed leukaemia [17]. In addition
to improving the safety, there are also studies that showed
that the dissemination of the vectors in solid tumours
needed to be improved in order to reach clinical efficacy.
Lentiviral vector is a new type, more complicated retrovi-
ral vectors, which are primarily based on Human or
Bovine Immunodeficiency Virus. They have all the unique
features of MoMLV and have been shown to transduce
post mitotic cells in vitro and in vivo [18]. Studies with the
Human Immunodeficiency Virus (HIV)-based vectors
have shown efficient gene transfer in tumour models.
Since HIV is a human pathogen, there was a tenancy of
reluctant use in human patients even though a clinical
trial assessing use of lentoviral vector for the therapy of
AIDS is underway [19]. Thus, several bovine based vector
systems were developed, which have the advantage of less
or no pathogenicity in humans or any seroconversion to
the original pathogen, thus, it was assumed that they carry
less disease potential than possible seroconversion of vec-
tors derived from human pathogens. We have also devel-
oped a bovine lentiviral vector system based on the
Jembrana Disease virus (JDV) [20,21]. JDV only causes
disease in a specific species of cattle in the Jembrana dis-
trict in Bali, Indonesia, but does not affect humans. Path-
ological changes include intense non-follicular lympho-
proliferation by reticulum and lymphoblastoid cells in
lymphoid organs. Follow up protein and genome
sequence studies have confirmed that JDV has a genome
of 7732 nt and structure and organisation similar to other
members of the lentivirus family. More importantly, JDV
possesses several features in common with HIV that are
very attractive as a vector, including the ability to replicate
to a high titre (about 108 plaque forming unit (PFU)/ml
of virus in the plasma), and being able to efficiently inte-
grate into chromosomes of non-dividing and terminally
differentiated cells. Most of the lentiviral vectors were
pseudotyped with a glycoprotein from the vesicular sto-
matitis virus (VSV), VSV-G, as it provided not only a broad
tropism, but also physical strength that enabled concen-
tration by centrifugation.
(B) Adenoviral vector (AV)
Adenovirus vector is the most commonly studied and
most widely used system in cancer gene therapy. They are
of particular utility for cancer gene therapy applications,
where temporary gene expression is acceptable or even
beneficial. The currently employed AVs in clinical trials
are all based on serotype 5. AV can be produced at high
titre and has demonstrated efficient gene transfer to vari-
ous types of cancer cells [22]. Two AVs have been
approved for clinical use in patients suffering from head
and neck cancers in China, one is the adeno-P53 [23], and
the other is a replication-competent adenovirus.
Several other adenoviruses, based on canine, porcine,
bovine, ovine and avian have all been developed. The
ovine AV is based on serotype 7 and developed in Aus-
tralia. Preclinical testing on prostate cancer in animal
models has shown therapeutic efficacy [24].
AVs contain many viral genes encoding major proteins
that elicit a strong host immune response. Of particular
concern is the development of cytotoxic T lymphocytes
that lyse cells expressing the recombinant genes. Newer
generations of AV vector were designed to overcome some
of these problems and the initial results were encouraging.
New techniques involved in removing the recombinant
viral genes and transfecting the non-recombinant plasmid
with a helper virus and then separating the helper virus
with sedimentation techniques were developed. Improve-
ments in helper virus have also been trialled that reduces
"floxed" helper virus production 1000-fold, but this
method still has a 1% wide type (WT) contamination thus
still allowing the possibility of in vivo recombination.
With regard to AV-mediated cancer treatment, high-level
tumour transduction remains a key developmental hur-
dle. To this end, AV vectors possessing infectivity enhance-
ment and targeting capabilities should be evaluated in the
most stringent model systems possible. Advanced AV-
based vectors with imaging, targeting and therapeutic
capabilities have yet to be fully realized; however, the fea-
sibilities leading to this accomplishment are within close
reach [25].
(C) Adeno-associated virus (AAV)-based vectors
AAV-based vectors have been shown to be non-toxic and
undergo widespread cellular uptake in preclinical evalua-
tion [26]. A recent study has compared five different AAV
strains and amongst them, serotype 2 was proved to be the
most efficient killers of tumour cells. In another study,
serotype 8 AAV vector encoding a soluble vascular
endothelial growth factor (VEGF) receptor was able to
halt tumour growth in several rodent glioma models.Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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However, difficulties in the development of packaging cell
lines for AAV, as well as bulk production and vector puri-
fication have been reported as problematic [27]. A new
system was developed recently to scale up and bulk pro-
duce of AAV from insect cells may solve some of these
existing problems [27].
(D) Herpesvirus-based vectors
Vectors based on herpesviruses are well-developed and
have progressed to clinical trials. As with other viral vec-
tor, replication defective vectors did not show much of
use. The first replication competent vector was based on a
mutant strain, where the vectors are deleted of the main
neurovirulence gene r34.5, which restricted its ability to
replicate in adult central nervous system and to form
latency. However, later study showed that the mutant
strain that had the deletion of the r34.5 gene also reduced
the capacity of replication inside tumour cells [28]. The
new vector has a deleted ICP47 gene instead without
impacting on efficient replication.
Pre-existing immunity may pose a problem that limits the
clinical efficacy of herpesvirus-based vectors. The immu-
nity prevented the transduction of peripheral organs and
also caused liver toxicity. However, a recent mutant strain-
secreting cytokine granule macrophage colony stimula-
tory factor (GM-CSF) or IL-12 was shown to be effective in
liver cancer therapy in a murine model which likely
involves both direct viral oncolysis and actions of specific
immune effector cells [29].
(E) Viral replicons and transposons
Semliki Forest virus (SFV) subgenomic replicons (i.e. non
toxic replication) have been developed that allow stable
expression of a required gene e.g. beta-galactosidase (beta-
Gal) in mammalian cell lines. Expression remained high
(approximately 150 pg per cell) throughout cell passages
[30].
Since construction of the Sleeping Beauty transposon
from defective copies of a Tc1/mariner fish element [31],
new vertebrate genetic manipulation tools (i.e. trans-
posase enzymes) have become available for gene therapy.
This particular transposase in the system binds to the
inverted repeats of salmonid transposons that surround
the insertion gene and mediate precise 'cut and paste' into
fish, mouse and human chromosomes. Potential prob-
lems with the use of transposons for gene therapy may
arise from having no 'off' switch for the transposase and
the relatively low quantities of integrated product, either
of which would make retroviral intergrase as a more suit-
able or alternative enzyme for chromosomal integration.
(F) Targeted viral vectors
While efforts have been focused on the continuing refine-
ment of various vector systems, several obstacles remain,
primarily the low efficiency of gene delivery into target
tumour cells. The vascular endothelial wall is a significant
physical barrier prohibiting access of systemically admin-
istered vectors to the tumour cell. To overcome this obsta-
cle, strategies are currently being developed to take
advantage of transcytosis pathways through the endothe-
lium. An AV vector targeted to the transcytosing transfer-
rin receptor pathway, using the bifunctional adapter
molecule had been constructed [32]. The transcytosed AV
virions retained the ability to infect cells, establishing the
feasibility of this approach. However, efficiency of AV traf-
ficking via this pathway is poor. Other efforts are directed
towards exploring other transcytosing pathways such as
the melanotransferrin pathway, the poly-IgA receptor
pathway, or caveolae-mediated transcytosis pathways.
There are hopes to develop mosaic AV vectors incorporat-
ing both targeting ligands directed to such transcytosis
pathways as well as ligands mediating subsequent target-
ing and infection of tumour cells present beyond the vas-
cular wall [33].
(G) Viral vector-associated multifunctional particles 
(MFPs)
Recently, a concept of multifunctional particles (MFPs)
based viral vectors has emerged. The idea incorporated
viral vectors' tumour targeting, imaging and amplifying
tumour killing capacities. AAV has been developed as
MFP, by virtue of genetic capsid modifications, to incor-
porate additional functionalities, such as modified fibres,
combined with imaging motifs on the pIX protein, to
simultaneously target tumour cells while monitoring viral
replication and spread. HSV TK has been incorporated at
pIX site of the AAV capsid. This enzyme is compatible with
available PET imaging ligands such as 18F-penciclovir,
providing an imaging system for viral replication that can
directly be translated for clinical applications. Interest-
ingly, HSV TK is an enzyme that has utility in so-called sui-
cide gene therapy, in which the expressed enzyme
converts a substrate such as ganciclovir to its phosphor-
ylated metabolite, which can then be further phosphor-
ylated by cellular kinases to a toxic metabolite, causing
cell death [34]. Also, tumour cells expressing this gene
product induce the death of adjacent cells via the so-called
'bystander effect', thus representing an 'amplifying strat-
egy' as mentioned above.
Nanotechnology has also been introduced recently in the
context of MFP. This is defined as the development of
devices of 100 nm or smaller, having unique properties
due to their scale. The devices that are being developed
generally incorporate inorganic or biological material. In
this regard, the coupling of inorganic nano-scale materialsGenetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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to targeted AV vectors has much potential. For example,
magnetic nano-particles have recently received much
attention due to their potential application in clinical can-
cer treatment; targeted drug delivery and magnetic reso-
nance imaging (MRI) contrast agents [35]. However,
despite the useful functionalities that might derive from
metal nanoparticle systems, the lack of targeting strategies
has limited their application to locoregional disease.
Thus, tumour-selective delivery is the key to improve ther-
apeutic applications of this technology.
Mechanisms of viral vector-mediated cancer 
gene therapy
(A) Corrective gene addition
The p53 tumour suppressor gene has received a great deal
of attention as a cancer therapeutic strategy due to the
important role it plays in maintaining the integrity of the
genome. It is involved in cell cycle regulation, DNA repair,
and apoptosis, essentially controlling the integrity of the
genome. Following exposure to DNA damaging agents,
p53 activation results in cell cycle arrest, allowing for DNA
repair or triggers cellular apoptosis if the damage is irrep-
arable. Thus, p53 mutations in cancer allows for unregu-
lated cellular proliferation in the face of genetic mutations
and accumulation of genetic errors contributing to the
malignant phenotype and genomic instability of cancer
cells. Preclinical studies have demonstrated that replace-
ment of wt-p53 in cancer cells through gene transfer tech-
niques restores p53  function and triggers apoptosis
leading to tumour cell destruction [36,37]. The effect is
selective to tumour cells with dysfunctional P53 as apop-
tosis is not triggered in normal cells containing wt-p53 fol-
lowing gene transfer.
Based on these preclinical studies a number of p53 gene
repair clinical trials have been initiated. These trials have
used different vector systems for gene transfer (retrovirus
and adenovirus), different routes of vector delivery (intra-
tumoural injection and bronchial lavage), and have
focused on different subtypes of lung cancer (non small
cell lung cancer, NSCLC and bronchioloalveolar carci-
noma). The first phase I clinical trial of such an approach
was conducted by Roth et al. at the M.D. Anderson Cancer
Centre [38]. In this trial, nine patients with advanced
NSCLC received intra-tumoural injections of a retroviral
vector containing p53  via CT-guided or endobronchial
injections. Effective gene transfer was demonstrated in
biopsied tumours following injection and some degree of
tumour regression of the injected lesion was seen in three
subjects providing proof-of-concept for this gene therapy
approach. All subsequent trials have utilized adenoviral
vectors for gene transfer since such vectors are relatively
easy to manufacture at large scale, can be produced at
higher viral titres, and have the ability to transduce both
dividing and non-dividing cells. Three adenoviral p53
(Ad-p53) single agent trials have been performed as well
as three Ad-p53 combination trials. Two of the single
agent trials were performed in advanced NSCLC using
either single or multiple vector injections [39]. These trials
demonstrated minimal toxicity, successful p53 gene trans-
fer, and transient injected lesion tumour regressions.
However, a similar proof-of-concept trial utilizing endo-
bronchial injections of an adenoviral vector containing
the marker gene, β-galactosidase, also showed localized
antitumour responses suggesting that the vector backbone
by itself might have antitumour activity regardless of the
transgene delivered [40]. Nevertheless, an important
observation was that effective gene transfer with minimal
toxicity could be achieved with repeated administration
even in the face of high-titre neutralizing anti-adenovirus
antibodies. Unfortunately no tumour regressions were
observed in non-injected lesions providing no evidence
for a clinically relevant systemic "bystander" killing effect.
Thus, the principal disadvantage of this treatment
approach is the theoretical need to genetically modify
every cancer cell in a tumour mass to achieve a maximal
anti-tumour effect. There were also reported trials of Ad-
p53 combined with chemotherapy [41], or radiation.
However, no obvious responses to the therapeutic were
observed. Early trials utilized p53 gene transfer as the sole
treatment modality whereas more recent trials have com-
bined p53 gene transfer with other cancer therapies, nota-
bly chemotherapy or radiation, as part of a combined
modality treatment approach.
(B) Suicide-gene therapy
This is also one of the well studied strategies and is based
on the delivery of a "suicide-toxin producing enzyme"
gene not normally found in mammalian cells to tumour
cells that allows for selective sensitivity to a systemically
administered pro-drug. One such suicide gene is the HSV
TK gene that codes for an enzyme that converts the nor-
mally nontoxic nucleoside analogue, ganciclovir, in sub-
sequent steps into a toxic compound that leads to tumour
cell death. Like the adenoviral p53  gene transfer
approaches described above, preclinical data with adeno-
viral HSV TK gene transfer (AdHSV TK) followed by gan-
ciclovir exposure results in a bystander effect in which
neighbouring, non-transduced cells are also being killed,
presumably due to transfer of toxic metabolites from the
transduced cells as well as induction of a generalized
immune response [42]. Preclinical studies in an immuno-
competent, orthotopic lung cancer model demonstrated
prolonged survival of mice inoculated with AdHSV TK
transfected tumour cells following treatment with ganci-
clovir compared with controls. While clinical data on this
approach has not been reported to date in lung cancer two
clinical trials utilizing an adenoviral vector to deliver the
HSV TK gene to patients with mesothelioma via intra-
pleural administration have been reported [43]. GeneGenetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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transfer was confirmed in more than half of the patients
and several partial tumour regressions were noted. Con-
comitant administration of systemic corticosteroids in an
attempt to suppress the anti-adenoviral immune response
in one of the two studies was ineffective, but did demon-
strate a trend toward increased gene transfer.
At present, the hurdle to clinical use of this strategy is the
low efficiency of gene transfer. To overcome the problem,
we also developed a novel way of using a unique peptide
to shuttle the HSV TK gene to neighbouring cells [44].
However, clinical efficacy has yet to be shown.
(C) Immuno-gene therapy
Several genetic strategies have been employed to enhance
the immunogenicity of tumours with a goal of inducing
immune-mediated tumour destruction. Unlike the gene
repair and suicide gene transfer studies described above,
immunogene therapies have the theoretical advantage of
inducing a systemic anti-tumour response associated with
immunologic memory. Such a response potentially
allows for treatment of disseminated disease and a pro-
longed anti-tumour effect that persists beyond the imme-
diate treatment period. Immunogene therapy strategies
involve both ex vivo and in vivo approaches. Early studies
of adoptive transfer of ex vivo expanded tumour infiltrat-
ing lymphocytes (TIL) demonstrated responses in
melanoma and renal cell cancer but activity in other solid
tumours was limited [45]. Systemic administration of
interleukin-2 (IL-2) appeared to enhance the activity of
TIL in some trials, but was associated with marked toxic-
ity. In an attempt to enhance the immunologic potency of
TIL without the associated toxicities of systemic IL-2
administration, genetic modification of TIL with the gene
for IL-2 has been studied. A phase I trial of IL-2 modified
autologous TIL in NSCLC has been completed. In this trial
TIL were harvested from malignant pleural effusions in
patients with NSCLC, genetically modified with an aden-
oviral vector containing the IL-2 gene, and reinfused into
the pleural cavity. Decreases in pleural effusions as well as
a partial tumour regression were noted among ten treated
patients. A second approach in preclinical development
involves genetic modification of dendritic cells with the
gene for interleukin-7 (IL-7). IL-7 stimulates cytotoxic T-
lymphocyte responses and down-regulates tumour pro-
duction of the immunosuppressive growth factor, TGF-β.
In murine models, intra-tumoural administration of den-
dritic cells modified with an adenoviral vector containing
IL-7 led to tumour regressions and immunologic memory
far superior to that seen with direct intratumoural injec-
tion of the AdIL-7 vector.
We have developed an ex vivo approach using the lentivi-
ral vector-mediated transfer of the tumour antigen gene
into dendritic cells (DCs) cells. Therapeutic effects were
demonstrated in up to 85% of the subjects [46].
(D) Anti-angiogenesis gene therapy
One of the features of the malignant tumours was the
increased vasculature. Therefore, targeting tumour vascu-
lature rather than the tumour cell itself as a treatment for
cancer has gained increasing interest in recent years. A
number of inhibitors of angiogenesis (e.g. angiostatin
[47], endostatin [48]) have been identified and have been
shown to induce tumour regressions in preclinical models
through inhibition of tumour neovascularization. An
alternative strategy to inhibit tumour angiogenesis is the
genetic delivery of genes with anti-angiogenenic proper-
ties directly to the tumour vasculature. One of the most
promising strategies in preclinical development involves
delivery of a mutant Raf gene to angiogenic blood vessels
using  αvβ3-targeted liposomes. The integrin, αvβ3, is
preferentially expressed in the angiogenic endothelium
and contributes to viral internalization making it a good
targeting molecule for anti-angiogenic gene therapy strat-
egies. Raf is a cellular signalling molecule that plays an
important role in neovascularization. Mice lacking Raf die
early in development with vascular defects and a mutant
form of Raf was shown to block angiogenesis in response
to pro-angiogeneic factors in vitro. Systemic injection of
targeted liposomes conjugated to a mutant Raf gene into
mice with pre-established lung and liver metastases from
colon carcinoma demonstrated predominant tumour
endothelial cell uptake, tumour endothelial cell apopto-
sis, and pronounced tumour regressions.
An alternative gene therapy strategy targeting the tumour
vasculature is a tumour vaccine targeting the vascular
endothelial growth factor receptor-2 (VEGF2, also known
as FLK-1). VEGFR2 has relatively restricted expression on
endothelial cells and is upregulated in proliferating
tumour neovasculature. An orally available DNA vaccine
encoding murine FLK-1 was shown to suppress angiogen-
esis in tumour vasculature, protect mice from lethal chal-
lenges with melanoma, colon, and lung carcinoma cells,
and reduce the growth of established metastases [49].
(E) Gene silencing
One of the newer technologies in cancer gene therapy
involves the silencing of genes in cancer cells that regulate
tumour cell growth and proliferation. We have developed
a double stranded RNA mediated silencing of the epider-
mal growth factor receptor (EGFR). In vitro studies have
demonstrated effective silencing of the EGFR and resulted
in the growth inhibition of NSCLC cells. A further study is
underway to demonstrate the in vivo efficacy of EGFR
silencing in animal models [50]"Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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Clostridial spores specifically target and deliver 
therapeutic genes to tumours
It is obvious that a major step towards the development of
an effective cancer therapy will be to construct a vector
that targets the tumour alone, and is capable of spreading
to and throughout the tumour found in tissues. Clostrid-
ial spores fit into this equation very well. Clostridia are
strictly anaerobic. They are gram-positive, rod-shaped,
and form spores under unfavourable conditions. There
are about 80 species and several of these have been tested
in solid tumours. All known species require anaerobic
conditions to grow but do vary in their oxygen tolerance
and their biochemical profile. Clostridial spores have
been administered intravenously and showed a distinct
advantage for use in cancer therapy as they are easy to pro-
duce and store. Germination of spores will only occur
when they encounter the requisite anaerobic conditions.
Spontaneous colonization of tumours in cancer patients
and the apparent selectivity of Clostridia for tumours were
noticed more than 50 years ago. The first experiment in
1947 showed that direct injection of spores of C. histolyti-
cum into mouse sarcoma caused oncolysis (liquefaction)
and tumour regression [51]. Later experiments proved this
selectivity by injecting mice i.v. with spores of C. tetani,
the causative agent of tetanus. Injected non-tumour bear-
ing animals remained healthy. However, tumour bearing
mice died within 48 h because of C. tetani colonisation
and tetanus production. This provided evidence that the
C. tetani were able to germinate/replicate selectively in the
anaerobic environment found within tumours, and
released their toxins systemically [52]. Obviously, it
would not be appropriate to use pathogenic strains of
Clostridia for clinical therapy in humans. A non-patho-
genic strain of C. butyricum M-55 has been isolated [53].
M-55 was later reclassified as C. oncolyticum and taxo-
nomic studies have now clearly established that it is a C.
sporogenes strain (ATCC13732). This is a proteolytic spe-
cies causing liquefaction of colonised tumours. This was
later verified by testing more isolates.
Saccharolytic clostridia, such as C. beijerinckii
NCIMB8052 spores administered intravenously to EMT6
tumour-bearing mice germinated in the necrotic tumour
regions while the oxygenated tumour areas remained free
of spores [54]. Equally, intravenous injection of rhab-
domyosarcoma-bearing rats with at least 107 spores of C.
beijerinckii  ATCC17778, C. acetobutylicum DSM792 (=
ATCC824) or C. acetobutylicum NI-4082 (reclassified as C.
saccharoperbutylacetonicum) showed tumour colonisa-
tion without complete tumour lysis [55].
C. sporogenes was the first Clostridium to be gene modified
and this was performed with the E. coli Colicin E3 gene.
Colicin E3 encodes a bacteriocin shown to have cancerio-
static properties [56]. However, the overall anti-tumour
efficacy of this bacteriocin was limited. This may have
resulted from poor gene modification methodologies
which were improved with the application of electropora-
tion. In 2002 Prof. Brown's group introduced E. coli cyto-
sine deaminase (CD) into C. sporogenes NCIMB10696 by
electroporation [57]. Intravenous injection of the recom-
binant spores followed by the systemic administration of
the prodrug 5-FC inhibited tumour growth which was
more pronounced than the use of prodrug alone. Unfor-
tunately, for reasons unknown this inhibition in tumour
growth did not persist. However, it was clear that C. sporo-
genes has a great capacity to colonise the tumour. At least
10e8 CFU/g of tumour was obtained following the intra-
venous injection of the spores (Table 1).
Saccharolytic Clostridia strains including C. beijerinckii
ATCC17778, C. acetobutylicum DSM792 (ATCC824) or C.
acetobutylicum NI4082 (reclassified as C. saccharoperbuty-
lacetonicum) and C. butyricum are non-pathogenic and
their development has been industry funded. Therapeutic
genes, encoding the cytokine tumour necrosis factor alpha
(TNF-α), CD or nitroreductase (NTR) have been intro-
duced into these strains [58,59]. Following transforma-
tion of C. acetobutylicum using strain-specific
electroporation protocols, CD expression was monitored
in lysates and supernatants of early logarithmic growth
phase cultures of recombinant C. acetobutylicum
(pKNT19closcodA) [12]. A considerable amount of heter-
ologous protein was expressed and efficiently secreted.
Also, C. acetobutylicum strains NI4082 and DSM792 engi-
neered to produce cytosine deaminase were able to
express and secrete this enzyme at the tumour site [58,59].
Functional CD enzyme was detected in the tumour of
rhabdomyosarcoma-bearing WAG/Rij rats that were
injected with the recombinant C. acetobutylicum, but not
in control animals. Animals, concomitantly treated with
antivascular chemical agent, CombreAp, showed higher
incidence of CD-positive tumours (100 versus 58%).
Moreover, the level of active CD in these tumour speci-
mens was considerably higher (mean conversion effi-
ciency of 5-FC to 5-FU ~11%) as compared to tumours
not treated with the vascular targeting drug (mean conver-
sion efficiency of 5-FC to 5-FU ~11%) when compared to
untreated tumours (mean conversion efficiency of 5-FC to
5-FU ~3%) [59]. However, when these recombinant
strains were used in solid tumour models in vivo, there was
a consistent lack of significant tumour regression
observed. Factors that may have contributed to this lack of
efficacy include a low level of bacterial colonisation of the
tumour or insufficient recombinant gene expression and
secretion at the tumour site [60]. Recent studies have
reported the development of vectors utilising super
tumour coloniser Clostridial  strains  C. sporogenes or  C.
novyi-NT. Recombinant C. sporogenes and  C. novyi-NT
overexpressing NTR showed significant in vivo anti-Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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tumour effects [61] when used with prodrug demonstrat-
ing the clinical potential of these vectors (Table 1).
Advantages of clostridial spores as "trojan 
horse" vectors for cancer gene therapy
At present, there are various gene therapy vector systems
under development against cancer. However, due to the
complexity of the solid tumours involving angiogenesis,
hypoxia, stromal cell, tumour cell heterogeneity and the
emergence of de-differentiated stem cells, none of the
existing vectors are holding any real promises. The
clostridial spore-based vector system is not infectious, and
has gained renewed interest, because of the following true
advantages.
(1) Safety
Safety is always a concern when live vector systems are
used for human gene therapy. Some of the hurdles of
using viral vectors include: (1) whether the vector is suffi-
ciently targeted to tumour alone; (2) whether the vector
expresses low levels of viral genes that may lead to
increased toxicity and immunogenicity [62]; (3) possible
immunogenicity of the transgene that may be reduced
with a reduction in the duration of gene expression [63];
and (4) whether viral particles are sequested within the
target cells or secreted into body fluid such as urine and
subsequently spread into environment. We postulate that
the use of clostridial spore based vectors may be a safer
option to using viral vectors. Clostridia are strictly anaer-
obic, are tumour targeted and would be unable to live in
non-hypoxic environments. A recent experiment with C.
novyi-NT has demonstrated that the strain was unable to
colonise artificially created infarcted heart where the level
of hypoxia was inadequate to support the replication of
the Clostridia. Early trials of non-pathogenic Clostridia
strains in patients have demonstrated safety. In the
unlikely event of an adverse effect, clostridia can be elim-
inated from the blood stream with the use of readily avail-
able antibiotics such as metronidazole which showed
total spore clearance from the blood stream after 9 days of
treatment [64].
(2) "Thriving on" the unique tumour microenvironment
The biological properties of virus-based vectors, in partic-
ular the ability to enter and replicate (in the case of repli-
cation-competent viral vectors) within a tumour cell and
then spread from cell to cell are highly relevant for effec-
tive cancer therapy. However, recent understanding of
tumour pathology has revealed that several features of the
tumour environment may not be conducive for viral rep-
lication [65,66]. Hypoxia is an important feature of solid
tumours and the ability of viruses to enter and replicate in
hypoxic cells may be a critical determinant for the success
or failure of viral vector-mediated cancer gene therapy.
Turning off protein translation is a central process in the
cellular adaptation to many types of stress, including viral
Table 1: Genetically modified recombinant clostridial strains and their antitumour studies.
Recombinant Strain Model Strategy/Result Reference
C. oncolyticum/sporogenesrecombinant for 
E. coli colicin E3
In vitro study Cancerostatic properties [56]
C. beijerinckii (acetobutylicum) 
recombinant for E. coli cytosine 
deaminase (CDase)
In vitro study and tested on murine EMT6 
carcinoma cell-line
Sensitivity to 5-fluorocytosine increased 
500-fold
[72]
C. beijerinckii (acetobutylicum) 
recombinant for Nitroreductase (NTR)
EMT6 Mouse
Prodrug: CB1954
CDEPT strategy with CB1954
Nitroreductase activity detected in 
tumor lysate
[54]
C. acetobutylicum recombinant for 
Tumour necrosis factor (TNF-α)
Rhabdomyosarcoma Recombinant protein detected in 
tumour, but no control of tumour 
growth
[58]
C. acetobutylicum recombinant for E. coli 
cytosine deaminase (CDase)
Rhabdomyosarcoma
Prodrug: 5-FC
CDEPT strategy
Cytosine deaminase activity detected in 
tumor lysate
[64]
C. sporogenes recombinant for cytosine 
deaminase (CDase)
SCCVII tumours into syngeneic C3H/
Km mice
Prodrug 5-FC
Growth delay of tumours [57]
C. acetobutylicum recombinant for 
interleukin-2 (IL-2)
Rhabdomyosarcoma Enhanced antitumour effect [60
C. sporogenes and C. novyi-NT 
recombinant for Nitroreductase (NTR)
Human colorectal carcinoma (HCT116) CDEPT strategy with CB1954
High level of colonization 108–109 cfu/g 
tumour.
Repeated CDEPT treatment cycle, 
significant tumour growth delay
[61]
Description of additional data files (N/A)Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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infection and hypoxia. The hypoxic cells, the apoptotic
cells, the quiescent cells are all refractory to viral entry and
replication [67]. This is a major problem for virus-based
vectors because if the vector can't reach a tumour cell, it
can't act or deliver a therapeutic gene. On the contrary,
clostridial spores are able to home in on these niche envi-
ronments because of their own unique metabolic need,
which enable them to utilise the tumour micro milieu and
respective tissues for their own proliferation. Both wild-
type and genetically modified Clostridia have been dem-
onstrated to specifically colonise and destroy solid
tumours. "Trojan horse" vectors have further created
improved features that enable them to kill tumour cells
through multimodality mechanisms.
(3) Easy production
All of the viral vector systems need sophisticated cell cul-
ture systems, expensive culture media, rounds of filtra-
tions and purifications and dedicated centrifugation and
storages. On the contrary, clostridial spores can be easily
and inexpensively produced from anaerobic bacterial cul-
ture. There are only a few steps involved and the spores,
once produced can be stored at room temperature for at
least 3–6 months.
(4) Easy administration
While most viral vectors have to be intratumourally
injected, intravenous injection of resuspended clostridial
spores are possible and sufficient as they will be leaked
out of the incomplete vessels in the solid tumour, thus
specifically targeting to and colonising the hypoxic
regions of the tumours.
(5) Destruction of all types of cells in the tumour, including 
stromal cells and stem cells
Solid tumours comprise not only malignant cells, but also
extracellular matrix and many other non-malignant cell
types, including stromal cells such as fibroblasts, endothe-
lial cells and inflammatory cells. The mechanisms of
clostridial vector-mediated tumour killing consist of sev-
eral aspects: one is from its transgene that encodes prod-
rug converting enzymes for suicide-gene therapy or
cytokines for immuno-gene therapy. These are essentially
the same as the viral vectors. However, there is another
side of the tumour killing effect that is resulting from the
consequences of an innate antitumour effect of the
clostridial strain due to production of hydrolytic enzymes
including proteases, lipases, and nuclease. Furthermore,
there is also a nutrients competition between the
clostridia and cells surrounding them (including tumour
cells, stromal cells and stem cells), where the clostridia
multiplied much faster than the mammalian cells. The
cumulative multiplications and the combined events of
energy and substance metabolism effectively depleted the
limited nutrient source and deprive the tumour cells,
causing starvation and death. More recently, there were
observations that indicate the germination of the clostrid-
ial spores, the transformation from spores to vegetative
rods, and the continue multiplications of the vegetative
rods inside the tumour activated the immune system,
assisting the antitumour effects [68]. These tumour killing
mechanisms destroy not only tumour cells, but also any
other cells in their vicinity. These are characteristics that
viral vectors are not so well equipped, nor any existing
convectional cancer therapies.
(6) Extracellular agent, no cell entry, no gene integration 
and no mutagenesis
While viral vectors need access to viable target cells and
their cellular machinery to achieve transgene delivery and
expression, this goal is often difficult to fulfil as some
tumour cells are not viable at the time of gene delivery.
Furthermore, none of the existing vector systems effi-
ciently transfer genes to every tumour cell which subse-
quently allows for tumour regrowth. On the other hand
clostridial spore replication is not tumour cell dependent
and occurs via rod multiplication extra-cellularlly. Fur-
thermore, the tumour killing mechanism of clostridial
spores may operate independently of the requirement for
gene transfer. Without the requirement for gene integra-
tion into the host cell genome removes the possibility of
insertional mutagenesis when using Clostridia. Therefore,
Clostridia may show tumour killing irrespective of the
tumour cell heterogeneity found within the tumour envi-
ronment.
(7) No limit on accommodating therapeutic genes
One of the primary limitations of most viral vectors has
been the small size of the virion, which only permits the
packaging of very limited sizes (usually a few kilobases) of
exogenous DNA that includes the promoter, the polyade-
nylation signal and any other enhancer elements that
might be desired. However, for clostridia size limitations
are far less restricted, not only because the plasmids used
can harbour much larger DNA fragments, but in case the
foreign gene is integrated in the host chromosome there is
in fact unlimited capacity for insertion of therapeutic
genes, forecasting the promising future for the develop-
ment of ever powerful vectors.
Conclusion
The unique pathophysiology of solid tumours presents a
huge problem for the conventional therapies. Thus, the
outcomes of current therapies are so far disappointing.
Several new approaches aiming at developing effective
treatments are on the horizon. These include a variety of
virus-based therapy systems [69-71]. Amongst all these,
replication-competent viral vector-mediated cancer ther-
apy is most promising [2,3]. However, even this system
suffers from several deficiencies: First, the vectors cur-Genetic Vaccines and Therapy 2008, 6:8 http://www.gvt-journal.com/content/6/1/8
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rently have to be injected intratumourally to elicit an
effect. This is far from ideal as many tumours are inacces-
sible and spread to other areas of the body making them
difficult to detect and treat. Second, because of the heter-
ogeneity within a tumour, the vector does not efficiently
enter and spread to sufficient numbers of tumour cells.
Third, hypoxia, a prevalent characteristic feature of most
solid tumours, reduces the ability of the viral vector to
function and decrease viral gene expression and produc-
tion. Consequently, a proportion of the tumour mass is
left unaffected and capable of re-growing. Fourth, pre-
existing immunity pose a problem for the efficacy of viral
vectors. Therefore, there have rarely been any cures with
the use of the system.
The strictly anaerobic clostridia, on the other hand, have
been shown to selectively colonise in solid tumours when
delivered systemically and has resulted in high percentage
of "cures" of experimental tumours. A phase I clinical trial
combining spores of a non toxic strain (C. novyi-NT) with
an antimicrotubuli agent has been initiated [10]. Genetic
manipulation of clostridia to make them into "Trojan
horse" vectors will provide further tumour killing mecha-
nisms and amplifying antitumour effects. Clearly, it is just
a matter of time that a "Trojan horse" type of clostridium
will become a clinical reality, especially if we can further
improve upon the system by providing additional fea-
tures, ideally including (i) targeting tumours only and not
anywhere else, (ii) able to effective kill primary tumours
as well as metastases. Current technologies are in place to
achieve these goals. Newer and effective therapies for solid
tumours based on the "Trojan horse" will be a reality in a
very near future.
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